Anthera totals $38m from public offering
This article was originally published in Scrip
Anthera Pharmaceuticals' brokers have sold an extra 4.95 million shares of common stock at $1 a share, exercising in full their over-allotments. The completed public offering thus raised a total of $37.95 million for the Hayward, California firm.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.